Intravesical BCG-therapy: Comparison of the adverse effects of connaught (Toronto) and Pasteur (Paris) strains;BCG-thérapie intravésicale : Comparaison des effets secondaires des souches Connaught (Toronto) et Pasteur (Paris)

Progres en Urologie

Volumn 10, Issue 4, 2000, Pages 542-547

  Champetier, Denis ^a   Valignat, Christophe ^a   Lopez, Jean Gabriel ^a   Ruffion, Alain ^a   Devonec, Marian ^a   Perrin, Paul ^a  

^a Hopital de l'Antiquaille   (France)

Author keywords

BCG therapy; Side effects; Superficial bladder tumour

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ARTICLE; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0034263688     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. BASSI P., PAPPAGALLO G.L., PIAZZA N., SPINADIN R., CARANDO R., MAZZARIOL C., BALTA G., PAGANO F. Low dose vs standard dose BCG therapy of superficial bladder cancer : final results of a phase III randomized trial. J. Urol., 1999, 161, 285.
2. BOCCON-GIBOD L. : La prévention des accidents de la BCG thérapie endovésicale. Prog. Urol., 1998, 8 (suppl.2), 22-23
3. BÖHLE A., BALCK F., VON WIETERSHEIM J., JOCHAM D. The quality of life during intravesical Bacillus Calmette-Guérin therapy. J. Urol., 1996, 155, 1221-1226.
4. BOHLE A., VON WIETERSHEIM J., JOCHAM D. : The balance between side-effects and success in intravesical therapy. Aspects of quality of life in BCG-treated patients. In a A. Böhle and D. Jocham Ed. : Optimal therapy for patients with high-risk superficial bladder cancer - controversy and consensus. Proceedings of the first Lübeck symposium on bladder cancer. The Medicine Publishing Foundation. 1997, 37, 109-117.
5. BOSTWICK D.G. : Natural history of bladder cancer. J. Cell. Biochem., 161, 31-38.
6. BROSMAN S.A. : Bacillus Calmette-Guérin Immunotherapy : Technics and results. Urol. Clin. North Am., 1992, 19, 557-564
7. COLOMB B., BALLEREAU C., MERIA P., LEGEAIS D., BISERTE J., MAZEMAN E. Etude retrospective comparant la tolérance et les complications du traitement par BCG endovésical dans les tumeurs superficielles de vessie entre les souches Immun Pasteur et Connaught. Prog. Urol., 1999, 9 (sup.1), 2 A.
8. DE BALINCOURT C.I., VAN DER MEIJDEN A.P.M., BRAUSI M., ZAMBON V., KIRKELS W., HOLTL W., BONO A., SYLVESTER R.J. et les membres de I'EORTC GU Group. Relationship between efficacy and side effects of BCG instillations in Ta-Tl bladder cancer : results of EORTC trial 30911. J. Urol., 1999, 161, 284.
9. DESGRANDCHAMPS F., LE DUC A. : Les risques cliniques liés à la BCG-thérapie endovésicale. Diagnostic et traitement. Prog. Urol., 1998, 8 (sup.2), 5, 13-19.
10. HERR H.W., SCHWALB D.M., ZHANG Z.F., SOGANI P.C., FAIR W.R., WHITEMORE W.F. Jr., OETTGEN H.F. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer : ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 1995 : 13, 1404-1408.
11. LAFONTAINE P.D., MIDDLEMAN B.R., GRAHAM S.D. Jr., SANDERS W.H. : Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology, 1997, 49, 363-366.
12. LAMM D.L. : Complications of bacillus Calmette-Guérin immunotherapy. Urol. Clin. North Am., 1992, 19, 565-572.
13. LAMM D.L. : BCG in perspective : Advances in the treatment of superficial bladder cancer. Eur. Urol., 1995, 27 (sup.1), 2-8.
14. LAMM D.L., STEG A., BOCCON-GIBOD L., MORALES A., HANNA M.G., PAGANO F. ALFTHAN O., BROSMAN S., FISHER H.A.J., JAKSE G., CHISOLM G.D., VAN DER MEIJDEN A.P.M., DEBRUYNE F.M.J. Complications of Bacillus Calmette-Guérin immunotherapy : review of 2602 patients and comparaison of chemotherapy complications. EORTC Genitourinary Group Monograph 6 : BCG in superficial cancer : 1989. Aan R. Liss, Inc., pp. 335-355.
15. LAMM D.L., STOGDILL V.D., STOGDILL B.J., CRISPEN R.G. : Complications of Bacillus Calmette-Guérin Immunotherapy in 1.278 patients with bladder cancer. J. Urol., 1986, 135, 272-274.
16. LAMM D.L., VAN DER MEIJDEN A.P.M., MORALES A., BROSMAN S.A., CATALONA W.J., HERR H.W., SOLOWAY M.S., STEG A., DEBRUYNE F.M.J. Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol., 1992, 147, 596-600.
17. MARTINEZ PINEIRO J.A., SOLSONA E., FLORETS N., ISORNA S. et le Cooperative Group CUETO : Improving the safety of BCG immunotherapy by dose reduction. Eur. Urol., 1995, 27 (sup.1), 13-18.
18. MORALES A., EIDINGER D. et BRUCE A.W. : Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol., 1976, 116, 180-183.
19. MUNGAN N.A., WITJES J.A. : Bacille CALMETTE-GUERIN in superficial transitional cell carcinoma. Br. J. Urol., 1998, 82, 213-223.
20. OATES R.D., STILMANT M.M., FREEDLUND M.C., SIROKY M.B. : Granulomatous prostatitis following Calmette-Guérin immunotherapy of bladder cancer. J. Urol., 1988, 140, 751-753.
21. PAGANO F., BASSI P., PIAZZA N., ABATANGELO G., DRAGO FERRANTE G.L., MILANI C. : Improving the efficacy of BCG immunotherapy by dose reduction. Eur. Urol., 1995, 27 (sup. 1), 19-22.
22. SALIOU P. : De l'Immun BCG frais Pasteur à l'Immucyst". Mise au point sur la BCG-thérapie endovésicale dans les tumeurs superficielles de vessie : risques et bénéfices. Prog. Urol., 1998, (supp.2), 3-4.
23. SCHELLHAMMER P.F., LADAGA L.E. et FILLION M.B. : Bacillus Calmette-Guérin for superficial transitional cell carcinoma of the bladder. J. Urol., 1986, 135, 261-264.
24. STASSAR M.J.G., VEGT P.D.J., STEERENBERG P.A., VAN DER MEIJDEN A.P.M., MEIRING H.D., DESSENS-KROON M., GEERTZEN H.G.M., DEN OTTER W. Effects of Isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. Urol. Res., 1994, 22, 177-184.
25. THALMANN G.N., STUDER U.E. : Fever as positive prognostic factor of BCG therapy. In A Böhle and D. Jocham Ed. : Optimal therapy for patients with high-risk superficial bladder cancer - controversy and consensus. Proceedings of the first Lübeck symposium on bladder cancer. The Medicine Publishing Foundation. 1997, 37, 119-124.
26. VAN DER MEIJDEN A.P.M. : Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur. Urol., 1995, 27 (supp. 1), 23-28.
27. VAN DER MEIJDEN A.P.M., VAN KLINGEREN B., STEERENBERG P.A., DE BOER L.C., DE JONG W.H., DEBRUYNE F.M.J. : The possible influence of antibiotics and tuberculostatics on result of Bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer. J. Urol., 1991, 146, 444-446.
28. VEGT P.D.J., VAN DER MEIJDEN A.P.M., SYLVESTER R., BRAUSI M., HOLTL W., DE BALINCOURT C. : Does isoniazid reduce side effects of intravesical Bacillus Calmette-Guérin therapy in superficial bladder cancer ? Interim results of European Organization for Research and Treatment of Cancer protocol 30911. J. Urol., 1997, 157, 1246-1249.
29. WITJES J.A., VAN DER MEIJDEN A.P.M., WITJES W.P.J., DOEZBURG W., SCHAAFSMA H.E., DEBRUYNE F.M.J. et les membres du Dutch South-East Cooperative Urological Group : A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Eur. J. Cancer, 1993, 29 A, 1672-1676.